Long-Term Motor and Cognitive Outcome of Deep Brain Stimulation in Patients With Parkinson Disease With a GBA1 Pathogenic Variant

BACKGROUND AND OBJECTIVES: genotype and DBS on long-term motor and nonmotor outcomes. METHODS: variant class and DBS target. No relevant differences emerged on stratification for variant classes or DBS targets, up to 3 years postsurgery. DISCUSSION: Despite its retrospective design, this study supports DBS as a valid therapeutic option for GBA-PD, providing prolonged benefits on motor symptoms and quality of life. The accelerated cognitive decline observed in GBA-PD, compared with non-mutated participants, was similarly present in both operated and non-operated groups, suggesting it is driven by the genotype rather than DBS itself. CLASSIFICATION OF EVIDENCE: -associated PD.